← Leaderboards
Daniel Paul Wermeling
Intranasal Technology, Inc.
$142,445
Attributed
$142,445
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $100K · FY2006–07$100K$75K$50K$25K$0
'06
'07
Funding mix
By agency
NIH$142,445 · 2
By mechanism
R41$100,000 · 1
M01$42,445 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAnimalsBiological AvailabilityClinically SignificantComputer Retrieval Of Information On Scientific Projects DatabaseDrug KineticsElectroporationExhibitsFormulations, DrugFundingGrantHourInnovationInstitutionIn VitroIn VivoNaltrexoneNaltrexone HydrochloridePersonal SatisfactionPharmaceutical PreparationsPlasmaPropertyProteinsPurpose